Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

Activaero GmbH. (2/2/11). "Press Release: Activaero Raises EUR 5.0 Million in a Second Closing Series".

Organisations Organisation Activaero GmbH
  Group Vectura (Group)
  Organisation 2 Life Sciences Partners Amsterdam
  Group Life Sciences Partners (LSP)
Products Product respiratory drug delivery technology
  Product 2 venture capital
Index term Index term Activaero–SEVERAL: investment, 201102 financing round €5m led by LSP Life Sciences Partners with €3.5m
Persons Person Neermann, Jörg (200701– Life Sciences Partners also Kaneas Capital founder before DVC before Atlas Venture)
  Person 2 Scheuch, Gerhard (Activaero 201105 CEO + Founder)

Activaero GmbH, a technology leader in controlled breathing inhalation devices, today announced that it has closed a further financing round of EUR 5.0 million (USD 6.8 million). LSP Life Sciences Partners of Amsterdam, the Netherlands, committed EUR 3.5 million and were joined by the existing investors BioMedPartners AG (advising BioMedInvest LP II), VI Partners AG, Abalis Finance AG, Vesalius Biocapital I SICAR S.A., MedVenture Partners GmbH and existing shareholders who contributed further EUR 1.5 million. The transaction was advised by MedVenture Partners GmbH.

Activaero will use the proceeds to further develop its proprietary pulmonary drug delivery technology and to establish further clinical activities.

Jörg Neermann, Partner at LSP, will represent LSP in Activaero's supervisory board. He commented: "Our investment is based on the excellent progress made by Activaero and its team since the first financing. The advancements within the current study on severe asthma are highly exciting. We are convinced of the growth potential Activaero is unfolding with its proprietary clinical programs and the impact it's controlled pulmonary delivery technology will have on the treatment of various pulmonary diseases."

Gerhard Scheuch, founder and CEO of Activaero said: "LSP was chosen as a top tier life science investor that will support us and our strategy to provide innovative devices and therapies to patients with severe lung diseases. We are happy to have them on board and we welcome Jörg Neermann to our supervisory board."

Record changed: 2017-04-02


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Vectura (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px

» top